Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-05

Clinical Trial Update: The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study [Phase 3]

View source ↗

Summary

Phase 3 trial of Trafermin for neuropathic diabetic foot ulcers completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trafermin (fibroblast growth factor-2 (FGF-2))

Snippet

Sponsor: Olympus Biotech Corporation | Conditions: Diabetic Foot Ulcer of Neuropathic Origin | Phase 3 | Status: COMPLETED | Results posted: 2014-08-05